A single gene edit aims to keep cholesterol and triglycerides low for good

A Nature paper describes base editing of the ANGPTL3 gene as a one-time route to lasting lipid reduction, still at the trial stage.

Nature has published work on using CRISPR base editing, delivered inside the body, to alter the ANGPTL3 gene. The aim is a durable drop in cholesterol and triglycerides from a single treatment. The approach is still in trials, not in routine use.

If it works, a one-time edit could stand in for lifelong drug regimens against cardiovascular disease. That would shift the cost from years of prescriptions to one procedure, and it would remove the daily burden of adherence. Those gains depend on the safety holding up over time.

We have only the headline and summary, not the paper's data, so trial size, results and side effects are unknown to us. The detail sits with Nature.

Source: Nature